Navigation Links
Safety and Efficacy of OrbusNeich's Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Date:1/10/2011

HONG KONG, Jan. 10, 2011 /PRNewswire/ -- Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and the accompanying requirement of long-term dual antiplatelet therapy (DAPT) showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention (published-ahead-of-print, August 2010).  

Known contraindications for DAPT include hypersensitivity or allergy to aspirin, a hemorrhagic risk, or a planned surgery shortly after percutaneous coronary intervention (PCI) that would require cessation of DAPT.

In the study, the major adverse cardiac events (MACE) free survival rate in patients treated with the Genous Stent was 80.6% after one year.  Between year one and year two, no additional MACE were observed. In patients who underwent surgical treatment shortly after PCI, no perioperative MACE or thrombotic events occurred.  Despite a very short period of DAPT use of 15 to 30 days, there were no cases of sub-acute, late or very late stent thrombosis in treated patients. The cumulative incidence of cardiac death was 1.6%, which is low considering the high risk patient population.

"The Genous Stent is an important and extremely attractive option for interventional cardiologists to safely manage high-risk patients who are contraindicated for prolonged DAPT and, therefore, should not receive a DES," said Paolo Scacciatella, M.D., Ph.D., of the Molinette Hospital Turin, Italy, and principal investigator of the study.  "This is the first study that demonstrates the feasibility and efficacy of the Genous Stent in this particular segment of patients who are challenging to treat."

Emanuele Meliga, M.D., Ph.D., FESC, of Ordine Mauriziano Hospital in Turin, Italy, and corresponding author of the publication added, "We have observe
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... On Aug. 20, at its annual meeting in ... voted on and approved a delegate resolution opposing the ... Cannabis Corp., a leading Canadian licensed producer of medicinal ... The CMA is quite right to point out that ... material, including medicinal cannabis. While some patients, particularly those ...
(Date:8/22/2014)... Equity Research highlights Epizyme (Nasdaq: EPZM - Free Report ... PNRA - Free Report ) as the Bear of the Day. ... FOLD - Free Report ), Sanofi (NYSE: SNY - ... ). Here is a synopsis of all five stocks: ... The biotech bull market is far from over due to ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... ARBOR, Mich., Nov. 9 Thomson Reuters ... a leading clinical surveillance solution that enables hospitals to ... improve clinical quality and reduce total cost of treatment. ... at no additional cost. , CareFocus 2.0 ...
... Nov. 9 Arcadia Resources, Inc. (NYSE Amex: ... care services under the Arcadia HealthCare(SM) brand, has appointed ... will replace Tres Lund who announced his resignation from ... http://www.newscom.com/cgi-bin/prnh/20091109/DE07521 ) , Goldsmith is the Daniel ...
Cached Medicine Technology:Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3
(Date:8/23/2014)... (PRWEB) August 23, 2014 Youth substance ... Texas. It’s no different in Houston, TX. Substance abuse ... falling victim to drug and alcohol dependency in higher ... looking to beat substance abuse, but don’t know where ... treatment facility can be a challenge because most treatment ...
(Date:8/23/2014)... 23, 2014 Teen substance abuse ranks as ... Holly Springs, NC. Countless adolescents throughout North Carolina struggle with ... Unfortunately, many never receive professional rehab due to a lack ... to get help. Troubled Teens Holly Springs is a helpline ... local teenage alcohol abusers in Wake County who ...
(Date:8/22/2014)... August 23, 2014 Search Engine ... the first page of search engines and get ... Hosting has recently compared many Linux hosting suppliers ... Bluehost are the most recommended Linux hosting suppliers ... and Europe to buy high quality Linux hosting ...
(Date:8/22/2014)... 2014 Deep Research Report on ... in-depth research report on the Glucose Meter market. ... Glucose Meter definition, classification, application, and industry chain ... covers the international market analysis, including domestic market ... environment & economic situation analysis. The report on ...
(Date:8/22/2014)... Recently, Skmen.com, an experienced supplier of ... bohemian dresses in its online store. Moreover, all these ... to 28% off. All the international clients can obtain ... 2014. , The company’s professional online workers update ... worldwide customers more the latest information about its new ...
Breaking Medicine News(10 mins):Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2
... ACNE TREATMENT EMBRACES DIFFERENCES IN MEN,S,AND WOMEN,S SKIN BY ... TREATMENT SOLUTION, SUMMIT, N.J., Oct. 30 Here,s ... between men and women are no more than skin,deep. ... care product, each,gender will be able to address these ...
... DENVER, Oct. 30 Air Methods Corporation,(Nasdaq: AIRM ) announces the ... Webcast, When: November 6, 2008 @ 4:15 ... Live over the Internet -- Simply log ... address above., Contact: Christine Clarke ...
... common gene variations may be responsible for much of ... New research on the MYH9 geneand its implications for ... the African American populationwill be summarized in a press ... Nephrology,s 41st Annual Meeting and Scientific Exposition in Philadelphia, ...
... Many with Eating Disorders, PHOENIX, Oct. 30 ... disorders are worried about treatment and not,seeking the help ... help for an eating disorder can be very,serious because ... Wall, PhD, director of psychological services at Remuda Ranch,Programs ...
... - Expands Therapy to Broader Patient Population -, ... Inc.,(NYSE: HSP ), a global specialty pharmaceutical ... Food and Drug Administration (FDA),approved a new indication ... This approval allows for use of Precedex in,non-intubated ...
... on a wide range of patient treatment experiences ... and features of ... Altrazeal(TM) -, LAS VEGAS, Oct. 30 ULURU ... application of Altrazeal(TM) -,Transforming Powder Dressing were presented yesterday at a special session,of ...
Cached Medicine News:Health News:Finally ... A Chance for Both Men and Women to Take CTRL(TM) of Their Own Skin! 2Health News:Finally ... A Chance for Both Men and Women to Take CTRL(TM) of Their Own Skin! 3Health News:MYH9 gene variations help explain high rate of kidney disease in African-Americans 2Health News:MYH9 gene variations help explain high rate of kidney disease in African-Americans 3Health News:MYH9 gene variations help explain high rate of kidney disease in African-Americans 4Health News:Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need 2Health News:FDA Approves New Indication for Hospira's Precedex (Dexmedetomidine HCL) Injection 2Health News:FDA Approves New Indication for Hospira's Precedex (Dexmedetomidine HCL) Injection 3Health News:FDA Approves New Indication for Hospira's Precedex (Dexmedetomidine HCL) Injection 4Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 2Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 3